Bromocriptine treatment of prolactinoma restores growth hormone secretion and causes catch-up growth in a prepubertal child

European Journal of Pediatrics

Volumn 163, Issue 8, 2004, Pages 472-474

  Sakazume, Satoru ^a   Obata, Kazuo ^a   Takahashi, Etsurou ^a   Yoshino, Atsunori ^a   Murakami, Nobuyuki ^a   Sakuta, Ryoich ^a   Murai, Takayasu ^a   Nagai, Toshiro ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bromocriptine; Growth hormone; Pituitary dysfunction; Prolactinoma

Indexed keywords

ARGININE; BROMOCRIPTINE; GROWTH HORMONE;

ADOLESCENT; ANAMNESIS; ARTICLE; BODY HEIGHT; CASE REPORT; CATCH UP GROWTH; CLINICAL FEATURE; DIAGNOSTIC IMAGING; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RETARDATION; HUMAN; HYPOPHYSIS; HYPOPHYSIS TUMOR; LABORATORY TEST; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREPUBERTY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SIDE EFFECT; TUMOR VOLUME;

EID: 3543046810     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-004-1454-5     Document Type: Article

References (11)

1. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G (1998) Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83: 2777-2780
2. Duntas LH (2001) Prolactinomas in children and adolescents - consequences in adult life. J Pediatr Endocrinol Metab 14[Suppl 5]: 1227-1232
3. Fideleff HL, Boquete HR, Sequera A, Suarez M, Sobrado P, Giaccio A (2000) Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 13: 261-267
4. George LD, Nicolau N, Scanlon MF, Davies JS (2000) Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin Endocrinol 53: 595-599
5. Gillam MP, Middler S, Freed DJ, Molitch ME (2002) The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 87: 4447-4451
6. Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws ER Jr, Groover RV, Kovacs K, Horvath E, Zimmerman D (1994) Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 79: 1135-1140
7. Nomikos P, Buchfelder M, Fahlbusch R (2001) Current management of prolactinomas. J Neurooncol 54: 139-150
8. Orrego JJ, Chandler WF, Barkan AL (2000) Pergolide as primary therapy for macroprolactinomas. Pituitary 3: 251-256
9. Partington MD, Davis DH, Laws ER Jr, Scheithauer BW (1994) Pituitary adenomas in childhood and adolescence. Results of trans-sphenoidal surgery. J Neurosurg 80: 209-216
10. Pontikides N, Krassas GE, Nikopoulou E, Kaltsas T (2000) Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary 2: 277-281
11. Rosenfeld GR (1996) Disorders of growth hormone and insulin-like growth factor secretion and action. In: Sperling MA (ed) Pediatric endocrinology. Saunders, Philadelphia, pp 117-160